Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

2007 (EUR 5.0 million in 2006);

- Net loss of EUR 7.3 million, against EUR 4.5 million in 2006; - Cash burn from operations remained limited at EUR 4.9 million (EUR 3.9 million in 2006);

- Consolidated cash and cash equivalents position increased to EUR 31.3 million at December 31, 2007 by issuance of new shares against EUR 24.0 million at December 31, 2006.

- Strategic progress in therapeutics

- New financial commitments from Allergan on the collaboration with the nomination in regulatory pre-development of a second compound resulting from the collaboration.

- Strengthened position in diagnostics

- Initiation of a new program in the field of blood diagnostic of prostate cancers in the framework of the collaboration signed with bioMerieux. To this end, ExonHit has initiated to the financing of clinical trials in Austria to speed the collection of blood samples.

- Development of the SpliceArray(TM) business

- Implementation and certification of an Affymetrix platform to equip a second service laboratory in Paris.

- Strengthened patent portfolio

- 10 new patents were filed in 2007, bringing the total of active patents filed since the Company's creation in 1997 to 177. 26 patents have been granted to ExonHit Therapeutics since its inception.

Bruno Tocque, President of the Management Board of ExonHit, commented: "We have reached our main objectives in 2007. We are very proud of the work accomplished by our collaborators in a context of market agitation which has been very disturbing for companies like ExonHit which invest in innovation with 65% of its operating expenses devoted to R&D.

We have kept our cash burn from operations below EUR 5 million while still investing more in R&D than in 2006. At December 31, 2007, we have an enviable cash and cash equivalent position of EUR 31.3 million. We will thereby have the capacity to continue our investment efforts, and notably in Alzheimer's
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to ... Tech , an e-Journal and producer of Food ... second year for the co-location of Food Labs Conference to ... that the registration fee to attend the two-day Food Lab ...
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... 15, 2014 Two champions of science, ... sponsorship of an annual competition for middle and high ... to, innovative STEM study. The competition presents students with ... of Engineering Aptitude, Mathematics, and Sciences is a ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... 2009 First Quarter Highlights , , , ... million in the first quarter of 2008 , ... first quarter of 2008 , Saflex ... The Company,s cash generation in the quarter allowed for debt ...
... 6 ChanTest, the leading expert in ion channels ... discovery, development, and safety -- is one of eight ... Research and Commercialization Program. Governor Ted Strickland and Interim ... of the Ohio Third Frontier Commission, Mark Barbash, announced ...
... - Aegera Therapeutics is pleased to announce the ... for AEG33773, a novel, orally bio-available small molecule ... neuropathy. , The Phase 2a study, entitled A ... and Efficacy of AEG33773 versus Placebo in Patients ...
Cached Biology Technology:Solutia Reports First Quarter 2009 Results 2Solutia Reports First Quarter 2009 Results 3Solutia Reports First Quarter 2009 Results 4Solutia Reports First Quarter 2009 Results 5Solutia Reports First Quarter 2009 Results 6Solutia Reports First Quarter 2009 Results 7Solutia Reports First Quarter 2009 Results 8Solutia Reports First Quarter 2009 Results 9Solutia Reports First Quarter 2009 Results 10Solutia Reports First Quarter 2009 Results 11Solutia Reports First Quarter 2009 Results 12Solutia Reports First Quarter 2009 Results 13Solutia Reports First Quarter 2009 Results 14Solutia Reports First Quarter 2009 Results 15Solutia Reports First Quarter 2009 Results 16Solutia Reports First Quarter 2009 Results 17Solutia Reports First Quarter 2009 Results 18Solutia Reports First Quarter 2009 Results 19Solutia Reports First Quarter 2009 Results 20Solutia Reports First Quarter 2009 Results 21ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 2ChanTest Awarded $4.8 Million Through the Ohio Third Frontier Research and Commercialization Program 3Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain 2
(Date:4/17/2014)... bone marrow need to produce hydrogen sulfide in order ... a new study from the Center for Craniofacial Molecular ... USC. , Professor Songtao Shi, principal investigator on the ... the cells governs the flow of calcium ions. The ... results in osteogenesis, or the creation of new bone ...
(Date:4/17/2014)... Clemson professor Rajendra Singh Thursday as a "Champion ... expand solar deployment in the residential, commercial and ... Professor of Electrical and Computer Engineering and director ... a local hero leading the charge across the ... solar power and driving policy changes at the ...
(Date:4/17/2014)... parasites and pathogens that devastate honeybees in Europe, Asia ... but do not appear to be impacting native honeybee ... of researchers., The invasive pests include including Nosema ... African honeybees appear to be resilient to these invasive ... to control pests in Europe, Asia and the United ...
Breaking Biology News(10 mins):White House honors Clemson professor as 'Champion of Change' for solar deployment 2East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... Center have discovered a basic mechanism by which smooth ... ?sometimes abnormally ?suggesting methods of treatment for various coronary ... involved in hypertension, coronary artery disease, tumors called leiosarcomas ... it is now possible to begin to design therapies ...
... different rates, and the evolutionary line that produced humans seems ... new study by scientists at the European Molecular Biology Laboratory ... very ancient ancestor that have been lost in more quickly-evolving ... genes in the first animals. The work appears in the ...
... warblers and beaver dams once were bountiful in an area ... left this area, elk grew more plentiful, browsing heavily on ... sparrows have replaced the warblers in what is now a ... of the wolf, a top predator. That's the compelling finding ...
Cached Biology News:UT Southwestern researchers unravel control of growing blood vessels 2The earliest animals had human-like genes 2The earliest animals had human-like genes 3Wolves' top-down effect 2